Key result
PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor within 5 minutes compared to placebo (P<0.001).
Why the study?
Bleeding is a concern with ticagrelor, its antiplatelet effects cannot be reversed with platelet transfusion, and a rapid-acting reversal agent would be useful.
Does PB2452 reverse the antiplatelet effects of ticagrelor in healthy volunteers?
RCT (n=64)
randomized
Does PB2452 reverse the antiplatelet effects of ticagrelor in healthy volunteers?
PB2452 provides immediate and sustained reversal of ticagrelor-induced platelet inhibition in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Rapid reversal may safely facilitate urgent procedures on ticagrelor; extends targeted antiplatelet reversal beyond transfusion limits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2019) conducted an RCT in Healthy volunteers (n=64). PB2452 vs. Placebo was evaluated on Ticagrelor reversal (increase in platelet function) (p=<0.001). PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor within 5 minutes compared to placebo (P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: